These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 21893499)

  • 21. Preventing relapse beyond 5 years: the MA.17 extended adjuvant trial.
    Goss PE
    Semin Oncol; 2006 Apr; 33(2 Suppl 7):S8-12. PubMed ID: 16730271
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endocrine manipulation in advanced breast cancer: recent advances with SERM therapies.
    Johnston SR
    Clin Cancer Res; 2001 Dec; 7(12 Suppl):4376s-4387s; discussion 4411s-4412s. PubMed ID: 11916228
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent results from clinical trials using SERMs to reduce the risk of breast cancer.
    Vogel VG
    Ann N Y Acad Sci; 2006 Nov; 1089():127-42. PubMed ID: 17261762
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Extended breast cancer treatment with an aromatase inhibitor (Letrozole) after tamoxifen: why, who and how long?
    Kaufmann M; Rody A
    Eur J Obstet Gynecol Reprod Biol; 2006 Jun; 126(2):146-54. PubMed ID: 16621229
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Progress in tailoring adjuvant endocrine therapy for postmenopausal women with early breast cancer.
    Bedard PL; Piccart-Gebhart MJ
    Curr Opin Oncol; 2009 Nov; 21(6):491-8. PubMed ID: 19593135
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identifying breast cancer patients most likely to benefit from aromatase inhibitor therapy after adjuvant radiation and tamoxifen.
    Freedman GM; Anderson P; Li T; Ross E; Swaby R; Goldstein L
    Cancer; 2006 Dec; 107(11):2552-8. PubMed ID: 17061250
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical importance of estrogen receptor-beta evaluation in breast cancer patients treated with adjuvant tamoxifen therapy.
    Honma N; Horii R; Iwase T; Saji S; Younes M; Takubo K; Matsuura M; Ito Y; Akiyama F; Sakamoto G
    J Clin Oncol; 2008 Aug; 26(22):3727-34. PubMed ID: 18669459
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Towards optimal endocrine therapy for hormone-sensitive breast cancer: initial versus sequential adjuvant aromatase inhibition.
    Spicer J; Ellis P
    Cancer Lett; 2007 Apr; 248(2):165-74. PubMed ID: 16919870
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estimating the benefits of adjuvant systemic therapy for women with early breast cancer.
    Grogan M; Tabar L; Chua B; Chen HH; Boyages J
    Br J Surg; 2001 Nov; 88(11):1513-8. PubMed ID: 11683751
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Are aromatase inhibitors superior to antiestrogens?
    Howell A; Buzdar A
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):237-47. PubMed ID: 15860266
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Informing women with breast cancer about endocrine therapy: effects on knowledge and adherence.
    Heisig SR; Shedden-Mora MC; von Blanckenburg P; Schuricht F; Rief W; Albert US; Nestoriuc Y
    Psychooncology; 2015 Feb; 24(2):130-7. PubMed ID: 24953538
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Adherence to endocrine therapy in breast cancer adjuvant and prevention settings.
    Chlebowski RT; Kim J; Haque R
    Cancer Prev Res (Phila); 2014 Apr; 7(4):378-87. PubMed ID: 24441675
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adherence to adjuvant therapy in post-menopausal breast cancer patients: a review.
    Banning M
    Eur J Cancer Care (Engl); 2012 Jan; 21(1):10-9. PubMed ID: 22004071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer.
    Partridge AH; Wang PS; Winer EP; Avorn J
    J Clin Oncol; 2003 Feb; 21(4):602-6. PubMed ID: 12586795
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Symptoms and QOL as Predictors of Chemoprevention Adherence in NRG Oncology/NSABP Trial P-1.
    Land SR; Walcott FL; Liu Q; Wickerham DL; Costantino JP; Ganz PA
    J Natl Cancer Inst; 2016 Apr; 108(4):. PubMed ID: 26615179
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adherence to adjuvant tamoxifen and associated factors in breast cancer survivors.
    Uslu Y; Kocatepe V; Sezgin DS; Uras C
    Support Care Cancer; 2023 Apr; 31(5):285. PubMed ID: 37079089
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Reasons for nonadherence to tamoxifen and aromatase inhibitors for the treatment of breast cancer: a literature review.
    Sawesi S; Carpenter JS; Jones J
    Clin J Oncol Nurs; 2014 Jun; 18(3):E50-7. PubMed ID: 24867124
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Adherence to adjuvant hormonal therapy and its relationship to breast cancer recurrence and survival among low-income women.
    Weaver KE; Camacho F; Hwang W; Anderson R; Kimmick G
    Am J Clin Oncol; 2013 Apr; 36(2):181-7. PubMed ID: 22314001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Understanding tamoxifen adherence in women with breast cancer: A qualitative study.
    Moon Z; Moss-Morris R; Hunter MS; Hughes LD
    Br J Health Psychol; 2017 Nov; 22(4):978-997. PubMed ID: 28850763
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identifying adherence barriers to oral endocrine therapy among breast cancer survivors.
    Paranjpe R; John G; Trivedi M; Abughosh S
    Breast Cancer Res Treat; 2019 Apr; 174(2):297-305. PubMed ID: 30523459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.